HC Wainwright reissued their buy rating on shares of Nuvalent (NASDAQ:NUVL – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $155.00 price target on the stock. A number of other analysts also recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a […]

HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a report published on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. PDSB has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of PDS […]

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $5.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential downside of 76.30% from the stock’s current […]

HC Wainwright reiterated their buy rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $200.00 price objective on the stock. HC Wainwright also issued estimates for Belite Bio’s Q1 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.75) […]

HC Wainwright reiterated their neutral rating on shares of Assertio (NASDAQ:ASRT – Free Report) in a research report sent to investors on Thursday morning, MarketBeat.com reports. HC Wainwright currently has a $18.00 price target on the stock, down from their prior price target of $35.00. Several other brokerages also recently weighed in on ASRT. Weiss […]